Thank you.
Your case study is available below!
Download your copy of “Gaining Regulatory Approval Following a Single-Arm Phase I/II Study” for an inside look at the journey one small biopharma sponsor took with Veristat to secure FDA and EMA approval of their ultra-rare and aggressive hematologic malignancy treatment.
Download case study
Gain new insights into the importance of partnering with an experienced CRO to create your successful approval and endpoint strategies for your rare and ultra-rare disease therapeutics.
Learn more about the importance of a thorough, well-planned strategy for demonstrating the unique benefits and risks of your rare disease treatments and cures. Download your free case study now for exclusive insights.
You May Also Like:
case study
“New Tumor Evaluation Modality”
For an inside look at how Veristat helped a sponsor partner apply itRECIST, download your free copy of “New Tumor Evaluation Modality: Using intratumor RECIST (itRECIST) criteria to measure effectiveness of cancer therapeutics”.
Access the case study
video case study
Decentralized solutions for pediatric Canavan disease trials
Discover how Veristat helped one sponsor successfully conduct a complex clinical trial further complicated by the restrictions of the COVID-19 global pandemic. Watch your free video case study to explore the decentralized solutions they applied to successfully overcome the challenges of pediatric rare disease participation and data collection.
Access the case study
podcast
Advancing Revolutionary Therapies (ART) Podcast: “Orphan Drug Designations and Orphan Subsets”
Listen now to the “Orphan Drug Designations and Orphan Subsets” podcast for expert insights into using the US FDA’s Orphan Drug Designation (ODD) program to realize sponsor benefits like tax credits for qualified trials, user fee exemptions, and the potential for seven years of market exclusivity after approval.
listen to the podcast
infographic
“Roadmap to Market for Cell and Gene Therapies”
The path to market for cell and gene therapies can be a winding one, full of unexpected turns and unwelcome detours. Don’t make the journey without a trusted guide. Download “Roadmap to Market for Cell and Gene Therapies” from Veristat for an inside look at successfully getting your therapeutics to patients.
View the infographic
Case Study
“Shortening Development and Approval Timelines for Novel Medicinal Products”
Download your free, snapshot view of the key benefits that 12 special designations can provide to rare disease drug developers.
Access the case study